HomeCompareEVCGX vs MRK

EVCGX vs MRK: Dividend Comparison 2026

EVCGX yields 1.73% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $34.6K in total portfolio value
10 years
EVCGX
EVCGX
● Live price
1.73%
Share price
$16.40
Annual div
$0.28
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$22.2K
Annual income
$192.88
Full EVCGX calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — EVCGX vs MRK

📍 MRK pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodEVCGXMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, EVCGX + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
EVCGX pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

EVCGX
Annual income on $10K today (after 15% tax)
$146.63/yr
After 10yr DRIP, annual income (after tax)
$163.95/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, MRK beats the other by $8,164.46/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of EVCGX + MRK for your $10,000?

EVCGX: 50%MRK: 50%
100% MRK50/50100% EVCGX
Portfolio after 10yr
$39.5K
Annual income
$4,995.51/yr
Blended yield
12.65%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

EVCGX
No analyst data
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

EVCGX buys
0
MRK buys
0
No recent congressional trades found for EVCGX or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricEVCGXMRK
Forward yield1.73%2.76%
Annual dividend / share$0.28$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$22.2K$56.8K
Annual income after 10y$192.88$9,798.13
Total dividends collected$1.8K$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: EVCGX vs MRK ($10,000, DRIP)

YearEVCGX PortfolioEVCGX Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$10,873$172.50$11,206$366.19$333.00MRK
2$11,809$175.28$12,650$502.35$841.00MRK
3$12,813$177.92$14,407$694.19$1.6KMRK
4$13,891$180.43$16,585$967.82$2.7KMRK
5$15,046$182.80$19,342$1,363.89$4.3KMRK
6$16,284$185.05$22,913$1,947.19$6.6KMRK
7$17,611$187.18$27,662$2,823.89$10.1KMRK
8$19,033$189.19$34,159$4,173.35$15.1KMRK
9$20,557$191.09$43,337$6,308.80$22.8KMRK
10$22,188$192.88$56,776$9,798.13$34.6KMRK

EVCGX vs MRK: Complete Analysis 2026

EVCGXStock

Under normal market conditions, the fund invests at least 80% of its net assets (plus any borrowings for investment purposes) in equity securities of companies located in the China region (the "80% Policy"). It invests primarily in common stocks of companies that, in the opinion of the investment sub-adviser, will benefit from the economic development and growth of the People's Republic of China. The fund may invest 25% or more of its total assets in securities in any one country in the China region. It may invest up to 20% of its net assets outside the China region. The fund is non-diversified.

Full EVCGX Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this EVCGX vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

EVCGX vs SCHDEVCGX vs JEPIEVCGX vs OEVCGX vs KOEVCGX vs MAINEVCGX vs JNJEVCGX vs ABBVEVCGX vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.